Chinese pharmaceutical companies from "introducing" to "going out"

In recent years, the policy environment of domestic innovative drug research and development has been greatly improved, and capital has also been favored for innovative drugs.
Domestic pharmaceutical companies continue to increase the layout of innovative drugs, at the same time, multinational pharmaceutical giants research and development efficiency is reduced, facing the adjustment of product pipelines, and small and medium-sized European and American pharmaceutical resources are limited, have entered the Chinese market through cooperation with domestic pharmaceutical companies.
a variety of factors for the introduction of domestic (License-in) model projects to provide a good opportunity, while capable pharmaceutical companies have begun to go out, "License-out" projects are becoming more and more.
Introduction (License-in) Project 2010-2019, domestic pharmaceutical companies introduced a total of 558 overseas projects, mainly through drug development-commercial licensing, early drug research and development cooperation, drug patent licensing and divestiture of foreign assets to obtain drugs.
, drug development-commercialization licensing accounted for the highest proportion, at about 72%.
this section analyses a total of 517 projects with a relatively large share of 401 drug development-commercial licensing projects and 116 drug early development cooperation projects.
(Source: Coreways Trading Database, Data Interception Time 2020.02) (Source: Corey Weian, Cortellis Trading Database, Data Interception Time 2020.02) The five domestic pharmaceutical companies that introduced the largest number of foreign projects were: Reding Pharmaceuticals, Sansheng Pharmaceuticals, Kangzhe Pharmaceuticals, Baiji Shenzhou and Synthe Pharmaceuticals.
, Reding Pharmaceuticals ranked first, the introduction of 13 projects, Sansheng, Kangzhe ranked second, the introduction of 9 projects.
PARP inhibitor Nirapali (commodity name: Erle) is a typical representative of the introduction model of Reding Pharmaceuticals, which was listed on Chinese mainland in December 2019, and Reding Pharmaceuticals is also a typical import company.
and Sansheng Pharmaceuticals' representative drug, the Essena peptide microcell, is Also AstraZenecon's exclusive licensed drug.
(Source: Cortellis Trading Database, Data Interception Time 2020.02) 401 drug development-commercial licensing projects were counted because most of the 116 early drug development cooperation projects did not disclose specific amounts.
, the largest number of contracts was "$50 million", with a value of 67.
second and third place were the projects with total signings of $51-100 million and $101-150 million, which showed that the higher the total number of contracts, the smaller the number of transactions.
(Source: Corevican, Cortellis Trading Database, data interception time 2020.02) From the field of treatment, the largest number of the introduction of anti-cancer drugs, the number of 192, infection, ADHD drugs ranked second and third, respectively, the number of 80, 53.
(Source: Cortellis Trading Database, Data Interception Time 2020.02) More than half of the regions where Chinese pharmaceutical companies have introduced projects in the past decade are located in the United States (51.8%), with South Korea (6.4%), the United Kingdom (5.4%) and Japan (4.8%).
-out project In the past decade, domestic pharmaceutical companies have authorized overseas projects, including 104 development-commercialization licenses and 111 pharmaceutical early research and development cooperation projects, but only two of them have disclosed transactions.
104 development-commercial licensing projects, there has been a significant increase in out-of-country projects over the past five years, and as many as 15 in 2018.
(Source: Corey Weian, Cortellis Trading Database, Statistics Development-Commercial Licensing Project, Data Interception Time 2020.02) The largest number of projects authorized by domestic pharmaceutical companies to foreign countries are Hengrui Pharmaceuticals and Fuhong Hanxuan, each with four products licensed for overseas development.
Hengrui authorized products for BTK inhibitors, JAK inhibitors and PD-1 antibodies, Fuhong Hanyu authorized products for macro-molecular biological drugs, adaptive for anti-tumor.
(Source: Corey Weian, Cortellis Trading Database, Data Interception Time 2020.02) Hengrui has been a typical representative of Chinese pharmaceutical companies going out in recent years, but there have been failures.
September 2015, Hengrui signed a cooperative development agreement with Incyte for PD-1 single-anti-SHR-1210 (i.e., Karelli-Zhu single-resistance), and Hengrui licensed the exclusive development and marketing rights of SHR-1210 worldwide, excluding China, to Incyte.
deal totaled $795 million.
in February 2018, the parties announced the termination of the transaction.
April 2020, Henrui signed an agreement with CG Korea to license the Karelli Pearl project to CG gong for a total transaction value of $87.75 million, while obtaining a share of CG's sales.
January 2018, Henrik licensed BTK inhibitors SHR-1459, SHR-1266 to TG Therapeutics and JAK1 inhibitors SHR-0302 to Arcustis in a total transaction value of $350 million and $223 million, respectively.
the introduction of domestic drugs the largest number of foreign pharmaceutical companies: Japan's Mitsubishi Tianbian Pharmaceutical 4, HUYA biosciences 3, Amerigen, Cipla, Lilly and other 2 items.
Among the overseas varieties authorized by Chinese pharmaceutical companies, from the point of view of adaptive diseases, the largest number of anti-cancer drugs, the number of 39, infection, ADHD drugs ranked second and third, respectively, the number of 11, 10.
(Source: Corey Weian, Cortellis Trading Database, Data Interception Time 2020.02) Since China's accession to the WTO in 2001, China's pharmaceutical industry has ushered in a period of great development.
from the early exports of pharmaceutical raw material intermediates, to the export of chemicals and biologics, to the overseas licensing of innovative drugs in recent years and the U.S. listing of Zebtini, the international participation of Chinese pharmaceutical companies has been increasing.
chinese pharmaceutical companies are also gradually deepening their global reach.
"introduced" in order to better "go out".
believe that in the future there will be more and more high-quality domestic drugs to go out and blossom all over the world.
.